Myriad ( Myriad )

Myriad

Myriad's picture

Myriad is dedicated to providing patients and physicians with clinically important information globally. As part of this, Myriad has established International Headquarters in Zurich, Switzerland, a full service laboratory in Munich, Germany and sales offices in Munich, Germany, Paris, France, Madrid, Spain, Milan, Italy and Zurich, Switzerland. Additionally, we are working with a number of distributors globally.

Myriad press release, blog etc

01/03/2018 - 05:01 Myriad Genetics Announces Expanded Research Collaboration with AstraZeneca
12/12/2017 - 05:29 Myriad's BRACAnalysis CDx Test Effectively Identified Metastatic Breast Cancer Patients with Improved Outcomes from Pfizer's PARP Inhibitor, Talazoparib
12/08/2017 - 15:56 Myriad Genetics Presents Results From Two Important EndoPredict Studies at the 2017 San Antonio Breast Cancer Symposium
12/06/2017 - 15:31 Myriad Genetics Presents Pivotal Validation Study for New riskScore Test at the 2017 San Antonio Breast Cancer Symposium
11/10/2017 - 05:49 Myriad Collaborates with Department of Veterans Affairs in Large Trial Evaluating the GeneSight Test to Improve Mental Health Outcomes for Veterans
11/06/2017 - 07:54 Myriad Genetics Collaborates with CareFirst BlueCross BlueShield on Coverage with Evidence Development (CED) Study for the Vectra DA Test
11/02/2017 - 07:19 Myriad Announces GeneSight Psychotropic Results from a Large Prospective Trial in Patients with Major Depressive Disorder
10/30/2017 - 05:57 Crescendo Bioscience Announces Six Presentations at the American College of Rheumatology 2017 Annual Meeting
10/26/2017 - 05:17 EndoPredict (EPclin) Shown in Second Study to be More Effective than Oncotype DX (RS) in Women with Intermediate Risk of Breast Cancer Recurrence
10/24/2017 - 04:36 Myriad Submits BRACAnalysis CDx Application for Regulatory Approval in Japan for HER2- Metastatic Breast Cancer
10/19/2017 - 08:01 GeneSight Shown to Statistically Significantly Improve Generalized Anxiety Disorder Treatment Response and Decrease Benzodiazepine Use
10/18/2017 - 05:20 Myriad's BRACAnalysis CDx Supplementary PMA Accepted by FDA for Review as a Companion Diagnostic for Lynparza (olaparib) in Metastatic Breast Cancer
10/02/2017 - 04:08 Myriad Genetics Highlights Strong Commitment to Preventing and Fighting Breast Cancer as Part of Breast Cancer Awareness Month
09/15/2017 - 08:01 Myriad Genetics Announces Positive Data Supporting New riskScore Test at the 36th Annual Conference of the National Society of Genetic Counselors
09/12/2017 - 03:31 Myriad Genetics to Present Three Studies at the 2017 National Society of Genetic Counselors Annual Conference
09/07/2017 - 10:07 Hereditary Cancer Risk Assessment Is an Important Option for Prostate Cancer Patients during Prostate Cancer Awareness Month
09/05/2017 - 13:28 Myriad Launches riskScore Beginning the Next Epoch in Hereditary Cancer Testing
08/30/2017 - 04:51 Myriad Genetics to Present at the 2017 Morgan Stanley Global Healthcare Conference